https://www.biospace.com/apellis-pharmaceuticals-to-host-a-fireside-chat-at-the-6th-annual-evercore-isi-healthconx-conference
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx...
Jul 30, 2024 - Apellis Pharmaceuticals, Inc., announced that the company will host a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November...
https://www.biospace.com/apellis-announces-fda-acceptance-and-priority-review-of-the-new-drug-application-for-pegcetacoplan-for-the-treatment-of-pnh
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan...
Nov 17, 2020 - Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the U.S. Food and Drug Administration has...
https://www.marketscreener.com/quote/stock/APELLIS-PHARMACEUTICALS-I-38607086/positions/
Apellis Pharmaceuticals, Inc.: Top Mutual Funds Holders | APLS | US03753U1060 | MarketScreener
Apellis Pharmaceuticals, Inc.: List of funds which have big positions opened on Apellis Pharmaceuticals, Inc. | Nasdaq: APLS | Nasdaq
top mutual fundsapellispharmaceuticalsincholders
https://www.plus500.com/en-li/instruments/apls
Apellis Pharmaceuticals (APLS) CFDs
Track the latest Apellis Pharmaceuticals stock price at 40.83 with a 0.06% daily change (indicative prices). Buy/sell Apellis Pharmaceuticals (APLS) share CFDs.
apellispharmaceuticalsaplscfds
https://www.benzinga.com/quote/APLS/news
Latest Apellis Pharmaceuticals Stock News | NASDAQ:APLS | Benzinga
Get the latest news on Apellis Pharmaceuticals stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on APLS performance
stock newslatestapellispharmaceuticalsnasdaq
https://www.plus500.com/en-nl/instruments/apls
Apellis Pharmaceuticals (APLS) CFDs
Track the latest Apellis Pharmaceuticals stock price at 40.83 with a 0.06% daily change (indicative prices). Buy/sell Apellis Pharmaceuticals (APLS) share CFDs.
apellispharmaceuticalsaplscfds
https://finviz.com/news/341091/biogen-to-acquire-apellis-enhancing-the-companys-growth-portfolio-in-immunology-and-rare-disease-bolstering-growth-outlook-and-accelerating-expansion-into-nephrology
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease,...
Stock screener for investors and traders, financial visualizations.
https://geographicatrophy.com.au/
Geographic Atrophy | Homepage | Apellis
Resources and Information on Geographic Atrophy or Advanced Dry Age-Related Macular Degeneration Intended for Australian Healthcare Professionals
geographic atrophyhomepageapellis
https://www.benzinga.com/insights/analyst-ratings/24/07/39821621/peeling-back-the-layers-exploring-apellis-pharmaceuticals-through-analyst-insights
Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights - Apellis...
the layerspeelingbackexploringapellis
https://www.benzinga.com/analyst-ratings/price-target/21/07/21827909/10-biggest-price-target-changes-for-friday
10 Biggest Price Target Changes For Friday - American Well (NYSE:AMWL), Apellis Pharmaceuticals Inc...
Jul 2, 2021 - Credit Suisse raised the price target for Capital One Financial Corporation (NYSE: COF) from $122 to $135. Capital One Financial shares rose 1.6% to close at...
https://www.plus500.com/en/instruments/apls
Apellis Pharmaceuticals (APLS) CFDs
Track the latest Apellis Pharmaceuticals stock price at 40.83 with a 0.01% daily change (indicative prices). Buy/sell Apellis Pharmaceuticals (APLS) share CFDs.
apellispharmaceuticalsaplscfds
https://www.benzinga.com/quote/APLS/analyst-ratings
Apellis Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:APLS | Benzinga
Explore Apellis Pharmaceuticals analyst ratings and price targets (NASDAQ:APLS) on Benzinga. Stay updated on expert opinions and forecasts for APLS stock.
analyst ratingsprice targetsapellispharmaceuticalsnasdaq
https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33308090/apelliss-stock-under-pressure-on-syfovre-safety-concerns-analyst-slashes-price-targ
Apellis's Stock Under Pressure On Syfovre Safety Concerns: Analyst Slashes Price Target - Apellis...
Jul 20, 2023 - Since Friday, Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares have plummeted around 50% after the stock came under pressure following the disclosure of
https://www.plus500.com/en-bh/instruments/apls
Apellis Pharmaceuticals (APLS) CFDs
Track the latest Apellis Pharmaceuticals stock price at 40.83 with a 0.06% daily change (indicative prices). Buy/sell Apellis Pharmaceuticals (APLS) share CFDs.
apellispharmaceuticalsaplscfds
https://finviz.com/quote?t=APLS&ty=si&ta=1&p=d
APLS - Apellis Pharmaceuticals Inc Short Interest
APLS - Apellis Pharmaceuticals Inc - Stock screener for investors and traders, financial visualizations.
aplsapellispharmaceuticalsincshort
https://www.benzinga.com/analyst-ratings/23/11/35567579/21-analysts-have-this-to-say-about-apellis-pharmaceuticals
21 Analysts Have This to Say About Apellis Pharmaceuticals - Apellis Pharmaceuticals (NASDAQ:APLS)...
this to say21analysts
https://www.benzinga.com/insights/analyst-ratings/24/11/42108214/a-glimpse-into-the-expert-outlook-on-apellis-pharmaceuticals-through-20-analysts
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts - Apellis...
a glimpsethe expert
https://theorg.com/org/apellis-pharmaceuticals?person=stephanie-urbano-ponton
Apellis Pharmaceuticals | The Org
Apellis Pharmaceuticals is a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic compounds for autoimmune...
apellispharmaceuticals
https://www.fiercebiotech.com/biotech/apellis-beam-ink-75m-deal-to-bring-gene-editing-meds-to-complement-diseases
Apellis, Beam ink $75M deal to bring gene-editing meds to complement diseases | Fierce Biotech
Jun 30, 2021 - While a couple companies are making waves in gene editing, Beam Therapeutics is swimming in a different direction with the budding technology to help reset the...
https://finviz.com/quote?t=APLS&ty=dv&ta=1&p=d
APLS - Apellis Pharmaceuticals Inc Dividends
APLS - Apellis Pharmaceuticals Inc - Stock screener for investors and traders, financial visualizations.
aplsapellispharmaceuticalsincdividends
https://www.biospace.com/apellis-and-sobi-announce-positive-topline-results-from-phase-3-valiant-study-of-pegcetacoplan-in-c3g-and-primary-ic-mpgn
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in...
https://www.insidermonkey.com/blog/is-apellis-pharmaceuticals-inc-apls-the-best-stock-that-will-bounce-back-1528829/
Is Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back? - Insider Monkey
We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to take a look at where Apellis...
https://www.benzinga.com/news/earnings/22/07/28119727/dow-surges-500-points-johnson-johnson-lowers-guidance
Dow Surges 500 Points; Johnson & Johnson Lowers Guidance - Applied Digital (NASDAQ:APLD), Apellis...
Jul 19, 2022 - U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday.
https://www.biospace.com/press-releases/apellis-to-receive-up-to-300-million-from-royalty-purchase-agreement-with-sobi-for-ex-u-s-royalties-of-aspaveli-systemic-pegcetacoplan
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S....
https://www.plus500.com/en-sg/instruments/apls
Apellis Pharmaceuticals (APLS) CFDs
Track the latest Apellis Pharmaceuticals stock price at 40.83 with a 0.01% daily change (indicative prices). Buy/sell Apellis Pharmaceuticals (APLS) share CFDs.
apellispharmaceuticalsaplscfds
https://www.biospace.com/apellis-pharmaceuticals-enters-clinical-testing-phase-in-its-age-related-macular-degeneration-program
Apellis Pharmaceuticals Enters Clinical Testing Phase In Its Age-Related Macular Degeneration...
clinical testing
https://www.biospace.com/apellis-pharmaceuticals-reports-first-quarter-2024-financial-results
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results - BioSpace
May 8, 2024 - Apellis Pharmaceuticals, Inc., announced its first quarter 2024 financial results and business highlights.
first quarterfinancial resultsapellispharmaceuticalsreports
https://apellis.eu/
Official Home Page of the Apellis Pharmaceuticals Corporate Site | Apellis Pharmaceuticals
Aug 30, 2024 - Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are...
official home pageapellispharmaceuticalscorporatesite
https://www.benzinga.com/insights/analyst-ratings/25/02/43688570/what-6-analyst-ratings-have-to-say-about-apellis-pharmaceuticals
What 6 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Apellis Pharmaceuticals...
have to sayanalyst ratings6apellispharmaceuticals
https://www.insidermonkey.com/blog/hedge-funds-have-never-been-this-bullish-on-apellis-pharmaceuticals-inc-apls-3-798259/
Hedge Funds Have Never Been This Bullish On Apellis Pharmaceuticals, Inc. (APLS) - Insider Monkey
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
https://www.fxempire.com/stocks/apls/history
Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Price History | FXEmpire
Get in-depth historical insights into (APLS) Apellis Pharmaceuticals, Inc. Common Stock's stock performance. With data on prices, highs, lows, and change...
common stockprice historyapellispharmaceuticalsinc
https://www.biospace.com/apellis-pharmaceuticals-to-host-conference-call-on-august-1-2024-to-discuss-second-quarter-2024-financial-results
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024...
https://www.home.saxo/markets/stocks/apls-xnas
Apellis Pharmaceuticals Inc. stock | Saxo
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic...
apellispharmaceuticalsincstocksaxo
https://theorg.com/org/apellis-pharmaceuticals?person=marianne-lim-mendoza
Apellis Pharmaceuticals | The Org
Apellis Pharmaceuticals is a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic compounds for autoimmune...
apellispharmaceuticals
https://www.plus500.com/en-au/instruments/apls
Apellis Pharmaceuticals (APLS) CFDs
Track the latest Apellis Pharmaceuticals stock price at 40.82 with a -0.01% daily change (indicative prices). Buy/sell Apellis Pharmaceuticals (APLS) share...
apellispharmaceuticalsaplscfds